MiST is an open-label parallel-arm phase 2 trial which explored the efficacy of rucaparib, a PARP inhibitor, in patients with PM with BAP1-deficient or BRCA1-deficient mesothelioma pretreated with chemotherapy. The gene discussed is BRCA1; the disease is mesothelioma.